Chlordiazepoxide is a benzodiazepine sold in the U.S. under 5 brand and generic names, for alcohol withdrawal delirium and anxiety disorders. Below: what the FDA label says, every product that contains it, what the pills look like, and its recall record.
From the FDA label for Librelease (application NDA017813). Other chlordiazepoxide products — different forms, different strengths — are dosed differently. Follow the label for the one you were prescribed.
Because of the wide range of clinical indications for chlordiazepoxide HCl, the optimum dosage varies with the diagnosis and response of the individual patient. The dosage, therefore, should be individualized for maximum beneficial effects. ADULTS USUAL DAILY DOSE Relief of Mild and Moderate Anxiety Disorders and Symptoms of Anxiety 5 mg or 10 mg, 3 or 4 times daily Relief of Severe Anxiety Disorders and Symptoms of Anxiety 20 mg or 25 mg, 3 or 4 times daily Geriatric Patients , or in the presence of debilitating disease. 5 mg, 2 to 4 times daily Preoperative Apprehension and Anxiety On days preceding surgery, 5 to 10 mg orally, 3 or 4 times daily. If used as preoperative medication, 50 to 100 mg IM 1 hour prior to surgery. PEDIATRIC PATIENTS USUAL DAILY DOSE Because of the varied response of pediatric patients to CNS-acting drugs, therapy should be initiated with the lowest dose and increased as required. Since clinical experience in pediatric patients under 6 years of age is limited, the use of the drug in this age group is not recommended. 5 mg, 2 to 4 times daily (may be increased in some pediatric patients to 10 mg, 2 to 3 times daily) For the relief of withdrawal symptoms of acute alcoholism, the parenteral form is usually used initially. If the drug is administered orally, the suggested initial dose is 50 to 100 mg, to be followed by repeated doses as needed until…
The necessity of discontinuing therapy because of undesirable effects has been rare. Drowsiness, ataxia and confusion have been reported in some patients — particularly the elderly and debilitated. While these effects can be avoided in almost all instances by proper dosage adjustment, they have occasionally been observed at the lower dosage ranges. In a few instances syncope has been reported. Other adverse reactions reported during therapy include isolated instances of skin eruptions, edema, minor menstrual irregularities, nausea and constipation, extrapyramidal symptoms, as well as increased and decreased libido. Such side effects have been infrequent, and are generally controlled with reduction of dosage. Changes in EEG patterns (low-voltage fast activity) have been observed in patients during and after chlordiazepoxide HCl treatment. Blood dyscrasias (including agranulocytosis), jaundice and hepatic dysfunction have occasionally been reported during therapy. When chlordiazepoxide HCl treatment is protracted, periodic blood counts and liver function tests are advisable.
Same active ingredient — different manufacturer, form, price and FDA recall record. That last one is what our independent score measures.
| # | Drug | Rating | Type | Form | Generic? | Typical price | |
|---|---|---|---|---|---|---|---|
| 1 | 72/100 | Prescription | Capsule | Generic | $5 | View → | |
| 2 |
Imprint codes, colour and shape from the FDA’s labelling data. Match the imprint on your pill — or search any imprint.
| Imprint | Strength | Colour | Shape | Maker |
|---|---|---|---|---|
| CDPCD5;2;5 | 5 mg / 2.5 mg | green | capsule | — |
| WL;134 | 5 mg / 2.5 mg | white | capsule | — |
| VP302 | 5 mg / 2.5 mg | green | capsule | — |
| ML;5;2;5 | 5 mg / 2.5 mg | green | capsule | — |
| barr;159 | 25 mg | green, white | capsule | — |
| barr;159 |
A combination is a different drug — different dosing, different warnings. It is listed here so you can find it, not so you can substitute it.
Sources: FDA openFDA drug label, National Drug Code Directory, and Enforcement (recall) database. This page reproduces public FDA data and is not medical advice. Dosing is set by your prescriber.
Chlordiazepoxide HCl capsules are contraindicated in patients with known hypersensitivity to the drug.
The concomitant use of benzodiazepines and opioids increases the risk of respiratory depression because of actions at different receptor sites in the CNS that control respiration. Benzodiazepines interact at GABA A sites and opioids interact primarily at mu receptors. When benzodiazepines and opioids are combined, the potential for benzodiazepines to significantly worsen opioid-related respiratory depression exists. Limit dosage and duration of concomitant use of benzodiazepines and opioids, and monitor patients closely for respiratory depression and sedation.
| 72/100 |
| Prescription |
| Capsule |
| Generic |
| $5 |
| View → |
| 3 | Not yet rated | Prescription | Capsule | Generic | $5 | View → |
| 4 | Not yet rated | Prescription | Capsule | Generic | $5 | View → |
| 5 | Not yet rated | Prescription | Capsule | Generic | $5 | View → |
| 25 mg |
| green, white |
| capsule |
| — |
| barr;033 | 10 mg | black, green | capsule | — |
|---|
| MYLAN;277 | 10 mg / 27.98 mg | white | round | — |
|---|
| barr;159 | 25 mg | green, white | capsule | — |
|---|
| CA1 | 5 mg / 12.5 mg | green | round | — |
|---|
| CA2 | 10 mg / 25 mg | white | round | — |
|---|
| N36 | 5 mg / 2.5 mg | green | capsule | — |
|---|